Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06147999 · ClinicalTrials.gov registry record · NA
Impact of a Biophoton Therapy on Patients With Brain Disorders
A NA study of Brain Disorders - Alzheimer's Disease, Dementia, Parkinson's Disease, Traumatic Brain Injury, sponsored by First Institute of All Medicines.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06147999: Recruiting NA study of Brain Disorders - Alzheimer's Disease, Dementia, Parkinson's Disease, Traumatic Brain Injury, sponsored by First Institute of All Medicines.
NCT06147999 is a NA study of Brain Disorders - Alzheimer's Disease, Dementia, Parkinson's Disease, Traumatic Brain Injury that is actively recruiting participants, run by First Institute of All Medicines. The registered enrollment target is 80 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06147999, a NA study of Brain Disorders - Alzheimer's Disease, Dementia, Parkinson's Disease, Traumatic Brain Injury, is actively recruiting participants, sponsored by First Institute of All Medicines.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Previous clinical studies revealed that the newly developed biophoton therapy has been safe and effective in treating patients with Alzheimer's disease, dementia, stroke, traumatic brain injury, or Parkinson's disease. The current study is to confirm the previous clinical observation by conducting as a randomized, triple-blinded, placebo-controlled prospective intervention clinical research. About 80 patients with brain disorder (Alzheimer's disease, dementia, stroke, traumatic brain injury, Parkinson's disease) will participate in the intervention clinical study at the Tesla MedBed Center located in Butler, PA.
Primary Outcome
Short Form Health Survey (SF-36) will be used to assess life quality: scored from 0 (worst health) to 100 (best heath).
Conditions Studied
Interventions
- DEVICE Biophotonizer - a Biophoton Generator
Study Locations (1)
Pennsylvania
- Tesla MedBed Center, 139 Pittsburgh Road, Butler, PA 16001 - Butler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-11-08 |
| Est. Completion | 2026-11-08 |
| Phase | NA |
What NCT06147999 shows while recruiting
NCT06147999 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Brain Disorders - Alzheimer's Disease, Dementia, Parkinson's Disease, Traumatic Brain Injury appearing as the primary indexed condition, and to 1 intervention - of which Biophotonizer - a Biophoton Generator is the first listed.
NCT06147999 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06147999 about?
NCT06147999 is a clinical study titled "Impact of a Biophoton Therapy on Patients With Brain Disorders". Previous clinical studies revealed that the newly developed biophoton therapy has been safe and effective in treating patients with Alzheimer's disease, dementia, stroke, traumatic brain injury, or Parkinson's disease. The current study is to confirm the previous clinical observation by conducting a...
What is the current status of trial NCT06147999?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2023-11-08. Estimated completion is 2026-11-08.
What conditions does trial NCT06147999 study?
This clinical trial studies the following conditions: Brain Disorders - Alzheimer's Disease, Dementia, Parkinson's Disease, Traumatic Brain Injury.
What interventions are being tested in trial NCT06147999?
The interventions under investigation include: Biophotonizer - a Biophoton Generator (DEVICE).
Who is sponsoring clinical trial NCT06147999?
This trial is sponsored by First Institute of All Medicines, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06147999 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06147999's enrollment target sits among peer trials
80 994th of 2000 higher than 941 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI